Speed and nature of national comprehensive cancer network updates following food and drug administration approvals & withdrawals

We found that the NCCN rapidly incorporated new FDA-approved indications but, delayed updating FDA-withdrawn indications, removing them from guidelines in only a minority of cases. This work highlights a systemic pattern that may drive financial toxicity and suboptimal patient care, underscoring the need for two bodies for the optimal practice of oncologic medicine: one that guides clinicians on all potential treatment options without informing reimbursement coverage, and one that works to usher in cost-effective, evidence-based care to the US market.